Status:
TERMINATED
A Phase II Study of Maintenance With Azacitidine in MDS Patients
Lead Sponsor:
Groupe Francophone des Myelodysplasies
Collaborating Sponsors:
Celgene Corporation
Conditions:
Leukemia, Myelocytic, Acute
Myelodysplastic Syndromes
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
A phase II multicentre trial of maintenance with Azacitidine in MDS patients achieving complete or partial remission (CR or PR) after intensive chemoterapy. The primary objective is response duration...
Detailed Description
A academic multicentre study whose aims are to study the benefits of a maintenance therapy with 24 monthly courses af azacytidine in high-risk MDS patients, previously treated with intensive chemother...
Eligibility Criteria
Inclusion
- MDS with int 2 or high IPSS score eitherRAEB 1 or 2 according to the WHO classification (see appendix 1) or CMML with WBC \< 13 109/l RAEB-T according to the FAB classification (see appendix 1) without t(8 ;21), inv 16 or t(16;16) AML secondary to MDS (sAML) with a confirmed MDS phase of at least 2 months with available bone marrow cytogenetics at diagnosis of AML
- AND
- in CR or PR according to IWG criteria (see appendix 3) after one or two courses of predefined intensive chemotherapy (see page 12) with available cytogenetics at evaluation of response Aged 18 years of age or more Written Informed consent Adequate Contraception, if relevant Negative pregnancy test if relevant. Patients not eligible for the azacitidine confirmatory trial (azacitidine " versus " conventional treatment ") or unwilling to participate to it
Exclusion
- AML secondary to myeloproliferative or MDS/MPD WHO subgroups except CMML with WBC\< 13 109/l
- Therapy related MDS (after chemo or radiotherapy for a previous neoplasm or immune disorder)
- Patients eligible for allogeneic bone marrow transplantation (with a identified donor)
- Liver and/or kidney failures prohibiting the use of azacitidine. Creatininemia \> 1.5 normal value ALAT and ASAT \> 3N
- Bilirubin \> 2 N, unless due to dyserythropoiesis
- Known hypersensitivity to azacitidine or mannitol
- Other tumor, unstable for the last three years, except in situ uterine carcinoma or basal skin tumor
- Uncontrolled infection,
- WHO Performance status \> 2
- Life expectancy less than 3 months
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00446303
Start Date
July 1 2006
End Date
July 1 2010
Last Update
January 19 2012
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Amiens
Amiens, France, 80054
2
CHU Angers
Angers, France, 49033
3
CH d'Avignon
Avignon, France, 84000
4
CHU de Caen
Caen, France, 14033